DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tykerb (Lapatinib) - Current Clinical Trials

 
 



Tykerb Related Clinical Trials

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer [Recruiting]

Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb�) (PGT) [Recruiting]

Lapatinib and Cetuximab in Patients With Solid Tumors [Recruiting]

Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy [Recruiting]

Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer [Recruiting]

Regulatory Tykerb PMS [Recruiting]

A Short-Term Presurgical Study to Assess the Molecular Predictors of the Antiproliferative Effects of Lapatinib (GW572016) in Primary Breast Cancer [Recruiting]

Lapatinib and Circulating Tumor Cells in Breast Cancer [Recruiting]

Lapatinib With Sirolimus or Metformin [Recruiting]

Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment. [Recruiting]

A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval [Recruiting]

Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib [Recruiting]

Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer [Recruiting]

Concentration and Activity of Lapatinib in Vestibular Schwannomas [Recruiting]

Phase II Neoadjuvant in Inflammatory Breast Cancer [Recruiting]

Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects [Recruiting]

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors [Recruiting]

Lapatinib Ditosylate and MK2206 in Treating Women With Metastatic Breast Cancer [Recruiting]

Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells [Recruiting]

Study of How Well Letrozole Works in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer [Recruiting]

Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer [Recruiting]

A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab), TCL (Docetaxel, Carboplatin and Lapatinib) and the Combination of TCHL (Docetaxel,Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients. [Recruiting]

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma [Recruiting]

MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer [Recruiting]

Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab [Recruiting]

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents [Recruiting]

A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib [Recruiting]

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery [Recruiting]

Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer [Recruiting]

Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers [Recruiting]

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer [Recruiting]

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer [Recruiting]

Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-Line Therapy in HER2/Neu-Positive Breast Cancer [Recruiting]

A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors [Not yet recruiting]

A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) Versus Pemetrexed in Advanced Non Small Cell Lung Cancer [Not yet recruiting]

Neoadjuvant GW572016 to Treat Breast Cancer [Recruiting]

Ductal Carcinoma In Situ (DCIS) Lapatinib Trial [Recruiting]

Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC [Recruiting]

Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors [Recruiting]

Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma [Not yet recruiting]

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer [Recruiting]

Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast [Recruiting]

Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer [Recruiting]

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study [Recruiting]

Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer [Recruiting]

A Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer [Recruiting]

Phase I Study of Ixabepilone + Lapatinib +/- Capecitabine to Treat HER2 Positive Locally Advanced or Metastatic Breast Cancer [Recruiting]

A Phase II Trial of Lapatinib and Trastuzumab With or Without Endocrine Therapy in Locally Advanced HER2 Overexpressing Breast Cancer Patients [Not yet recruiting]

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer [Recruiting]

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 [Recruiting]

Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma [Recruiting]

LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients [Recruiting]

Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer [Recruiting]

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. [Recruiting]

Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer [Recruiting]

Phase II Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer [Recruiting]

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer [Recruiting]

Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer [Recruiting]

Letrozole and Lapatinib in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery [Recruiting]

Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery [Not yet recruiting]

Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer [Recruiting]

Phase I Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer [Recruiting]

Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors [Recruiting]

Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma [Recruiting]

Phase II Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy [Recruiting]

Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Head And Neck Cancer [Recruiting]

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-Naive Patients With Breast Cancer [Recruiting]

Lapatinib in Treating Young Patients With Recurrent or Refractory CNS Tumors [Recruiting]

Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer [Recruiting]

Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy [Recruiting]

Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx [Recruiting]

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy [Not yet recruiting]

INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients [Recruiting]

Combination Of Lapatinib With Carboplatin, Paclitaxel and Trastuzumab In Metastatic Breast Cancer [Recruiting]

Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer [Recruiting]

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer [Recruiting]

ErbB2 Over-Expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib [Recruiting]

Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors. [Recruiting]

A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib [Not yet recruiting]

Brain Metastases In ErbB2-Positive Breast Cancer [Recruiting]

Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer [Recruiting]

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer [Recruiting]

Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer [Recruiting]

Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China [Recruiting]

Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer [Recruiting]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014